A Phase 3 interventional study of ASTX727 and Dacogen in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia, sponsored by Astex Pharmaceuticals, Inc.. Completed at 84 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.
Sponsored by Astex Pharmaceuticals, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd. — 5 open to participants now, 7 under way, 2 of them phase 3. Myelodysplastic Syndromes · Otsuka Holdings Co., Ltd..
Among the 17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd., this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2018, is one of 4 in phase 3, and was the 5th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 323 are open to participants now.
Browse Myelodysplastic Syndromes studies →5 of the 17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd. are open now, in 12 countries. Recruiting first, the newest first:
Taiho Oncology, Inc. · Sites in United States, Armenia, Bulgaria and 5 more countries
Ages 18+
Taiho Oncology, Inc. · Sites in United States, Armenia, Bulgaria and 5 more countries
Ages 18+
Taiho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 20+
Taiho Oncology, Inc. · Sites in United States, Canada, Czechia and 7 more countries
Ages 18+
Taiho Oncology, Inc. · Sites in United States, Armenia, Austria and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 7 · Phase 3 5
First in 2001; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 227 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 70 across the 16 interventional studies, 16 across the 1 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Astex Pharmaceuticals, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Astex Pharmaceuticals, Inc. is the lead sponsor of 45 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 6 (46%) have results posted.
3 of the studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT04953910Taiho Oncology, Inc.Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment | 2026-12 |
| NCT04953897Taiho Oncology, Inc.Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment | 2026-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multicenter PK study of ASTX727 versus IV decitabine. Adult participants who were candidates to receive IV decitabine were randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine 20 mg/m\^2 Daily×5 in Cycle 2, or the converse order. After completion of PK studies during the first 2 treatment cycles, participants continued to receive treatment with ASTX727 from Cycle 3 onward (in 28-day cycles) until disease progression, unacceptable toxicity, or the participants discontinued treatment or withdrew from the study.
This Phase 3 study established PK equivalence of ASTX727 to IV decitabine in approximately 227 evaluable participants. Eligible participants were randomized to receive both study treatments: oral investigational drug ASTX727, and IV decitabine, as follows: participants were randomly assigned 1:1 to receive ASTX727 or IV decitabine in Cycle 1 and then cross over to the other therapy in Cycle 2.
In the ASTX727 cycle, participants received the ASTX727 tablet Daily×5. Serial PK measurements (blood draws) were done on Days 1, 2, and 5, along with pre-dose PK assessments on Days 1-5 and an assessment at 3 hours post-dose on Day 3. Participants were required to fast from food for 4 hours on days when receiving ASTX727: at least 2 hours before and 2 hours after dosing.
In the IV decitabine cycle, participants received a 1-hour infusion of IV decitabine 20 mg/m\^2 Daily×5. Serial PK measurements were done on Days 1 and 5, along with pre-dose and 1-hour post-infusion assessments on Day 3.
In Cycles ≥3, participants received the ASTX727 tablet Daily×5 in 28-day cycles. (No PK assessments were done from Cycle 3 onward.)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Men or women ≥18 years who are candidates to receive IV decitabine according to FDA or European Medicines Agency (EMA) approved indications:
Adequate organ function defined as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.
Drug: ASTX727 · Drug: Dacogen
Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.
Drug: ASTX727 · Drug: Dacogen
Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Drug: ASTX727 · Drug: Dacogen
Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Drug: ASTX727 · Drug: Dacogen
ASTX727 oral tablet
Also known as: decitabine 35 mg + cedazuridine 100 mg
Decitabine 20 mg/m\^2 one-hour IV infusion
Also known as: decitabine
Total 5-day Area Under the Curve From 0 to 24 Hours (AUC0-24) After Treatment With ASTX727 And IV Decitabine
Total 5-day ASTX727 AUC0-24 exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-24 (first ASTX727 dose) was added to (Day 2 AUC0-24+ Day 5 AUC0-24) × 2. Decitabine 5-day AUC0-24 exposures after IV decitabine were calculated as follows: (Day 1 AUC0-24+ Day 5 AUC0-24) / 2 was multiplied by 5. If AUC0-24 on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-24 on Day 5; the converse was also true.
Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)
MDS/CMML: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first.
Time frame: From randomization up to 30 days after last dose of study treatment (up to approximately 2.7 years)
AML: Number of Participants With Treatment-emergent Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first.
Time frame: From randomization up to 30 days after last dose of study treatment (up to approximately 2.4 years)
MDS/CMML: Number of Participants With Grade 3 or Higher TEAEs
TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first. Severity of AEs were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal.
Time frame: From randomization up to 30 days after last dose of study treatment (up to approximately 2.7 years)
AML: Number of Participants With Grade 3 or Higher TEAEs
TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first. Severity of AEs were graded using CTCAE version 4.03. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal.
Time frame: From randomization up to 30 days after last dose of study treatment (up to approximately 2.4 years)
Maximum Percentage of Long Interspersed Nucleotide Elements (LINE)-1 Demethylation
Summarized data for Cycle 1 and Cycle 2 was reported.
Time frame: Pre-dose on Day 1 of Cycles 1 and 2 (as Baseline), and Days 8, 15 and 22 of Cycles 1 and 2 (each cycle= 28 days)
Total 5-day Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine
Total 5-day ASTX727 AUC0-inf exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-inf (first ASTX727 dose) was added to (Day 2 AUC0-inf+ Day 5 AUC0-inf) × 2. Decitabine 5-day AUC0-inf exposures after IV decitabine were calculated as follows: (Day 1 AUC0-inf+ Day 5 AUC0-inf) / 2 was multiplied by 5. If AUC0-inf on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-inf on Day 5; the converse was also true.
Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)
Total 5-day Area Under the Curve From 0 to Last Quantifiable Concentration (AUC0-last) After Treatment With ASTX727 And IV Decitabine
Total 5-day ASTX727 AUC0-last exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-last (first ASTX727 dose) was added to (Day 2 AUC0-last + Day 5 AUC0-last) × 2. Decitabine 5-day AUC0-last exposures after IV decitabine were calculated as follows: (Day 1 AUC0-last + Day 5 AUC0-last) / 2 was multiplied by 5. If AUC0-last on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-last on Day 5; the converse was also true.
Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)
Total 5-day Area Under the Curve From 0 to 8 Hours (AUC0-8) After Treatment With ASTX727 And IV Decitabine
Total 5-day ASTX727 AUC0-8 exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-8 (first ASTX727 dose) was added to (Day 2 AUC0-8 + Day 5 AUC0-8) × 2. Decitabine 5-day AUC0-8 exposures after IV decitabine were calculated as follows: (Day 1 AUC0-8 + Day 5 AUC0-8) / 2 was multiplied by 5. If AUC0-8 on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-8 on Day 5; the converse was also true.
Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)
Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine
AUC0-inf was calculated using the formula AUClast + (Clast / λZ), where Clast is the last quantifiable concentration and λZ is the elimination rate constant. AUC0-inf will be calculated using the linear up-log down method. Summarized data has been reported for cycle 1 and 2.
Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)
Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer
Summarized data of Cmax on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of Cmax on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.
Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)
Time to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer
Summarized data of Tmax on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of Tmax on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.
Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)
Apparent Oral Clearance (CL/F) of Oral Decitabine and Cedazuridine
Oral CL/F for oral decitabine was measured only on Day 1 and oral CL/F for oral cedazuridine was measured on Days 1, 2 and 5. Summarized data of Oral CL/F for oral decitabine on Day 1 for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of oral CL/F for oral cedazuridine on Day 1,2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2 (each cycle= 28 days)
Apparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer
Summarized data of t1/2 on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of t1/2 on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.
Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)
Apparent Volume of Distribution (Vz/F) of Oral Decitabine and Cedazuridine
Summarized data of Vz/F on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2 (each cycle= 28 days)
MDS/CMML: Percentage of Participants With Complete Response (CR), Marrow CR (mCR), Partial Response (PR), Hematologic Improvement (HI) Based on International Working Group (IWG) 2006 Myelodysplastic Syndromes (MDS) Response Criteria
CR: normal peripheral, persistent granulocyte count ≥1.0x10\^9/liter(L), platelet ≥100x10\^9/L, Hemoglobin (Hgb) ≥11g/dL, normal bone marrow with persistent marrow blasts ≤5%. mCR: reduction of bone marrow blasts to≤5%, decrease by 50% or more with/without normalization of peripheral counts.PR: normal peripheral counts, granulocyte count ≥1.0x10\^9/L, platelet count ≥100x10\^9/L, Hgb ≥11 g/dL, normal bone marrow, marrow blasts \>5%, reduced by 50% or more for at least 4 weeks. HI: HI-E: Hb increase ≥1.5 g/dL in absence of RBC transfusions. HI-P: Absolute increase of platelet count from \<20 to \>20X10\^9/L by at least 100%,if more than 20x10\^9/L, by absolute increase of at least 30x10\^9/L in absence of platelet transfusions. HI-N: granulocyte increase ≥100%, by an absolute increase ≥0.5x10\^9/L for at least 8 weeks. Percentage of participants with CR, mCR, PR, and HI based on IWG 2003 MDS response criteria are reported. Response has been reported based on participants with MDS or CMML.
Time frame: Up to approximately 2.7 years
AML: Percentage of Participants With CR, CR With Incomplete Blood Count Recovery (CRi), CR With Incomplete Platelet Recovery (CRp), and CR Plus CRp Based on IWG 2003 AML Response Criteria
CR was defined as absolute neutrophil content (ANC) ≥1000/ microliter (μL), platelets ≥100,000/μL, independence from red blood cell (RBC) and platelet transfusions over the past week, no leukemic blasts and \<5% leukemic blasts. CRp was defined as CR criteria except platelets \<100,000/μL.and platelet transfusion over the past week. CRi was defined as CR criteria except ANC \<1000/μL or platelets \<100,000/μL. Percentage of participants with CR, CRi, CRp, and CR Plus CRp based on IWG 2003 AML response criteria are reported.
Time frame: Up to approximately 2.4 years
AML: Percentage of Participants With CR With Partial Hematologic Recovery (CRh) Based on IWG 2003 AML Response Criteria
CRh was defined as \<5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets \>50,000/μL and ANC \>500/μL), independence from RBC and platelet transfusions within 7 days of bone marrow evaluation, and peripheral blast ≤1%. Percentage of participants with CRh based on IWG 2003 AML response criteria are reported.
Time frame: Day 1 of Cycle 3 up to approximately 2.4 years (each cycle= 28 days)
AML: Time to First Response, Best Response and Complete Response Based on IWG 2003 AML Response Criteria
Time to first response was defined as time in months from the date of first treatment to the first date when any response is achieved. Time to best response was defined in months from the date of first treatment to the first date when a subject's best response, in the order of CR, CRi (or CRp or CRh), or PR, was achieved. Time to CR was defined in months from the date of first treatment to the first date when CR is achieved. CR:ANC ≥1000/ microliter (μL),platelets ≥100,000/μL,independence from RBC and platelet transfusions over the past week, no leukemic blasts, and \<5% leukemic blasts.CRp: CR criteria except ANC ≥1000/μL, platelets \< 100,000/μL.and platelet transfusion over the past week. CRi:CR criteria except ANC \<1000/μL or platelets \<100,000/μL.CRh: \<5% of blasts in the bone marrow,platelets \>50,000/μL and ANC \>500/μL, independence from RBC and platelet transfusions within 7 days and peripheral blast ≤1%. PR: CR criteria except decrease of ≥50% in leukemic blasts.
Time frame: Up to approximately 2.4 years
AML: Duration of Complete Response and Combined CR and CRh Based on IWG 2003 AML Response Criteria
Duration of CR was defined as the time interval from the first CR to time of relapse. Duration of combined CR and CRh was defined as the time interval from the first CR or CRh to time of relapse. Duration of CR and combined CR and CRh was presented using a Kaplan-Meier estimate.
Time frame: Up to approximately 2.4 years
MDS/CMML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI)
Transfusion independence was defined as no transfusion for 56 consecutive days or more (84 and 112 days) after the first dose of study treatment while maintaining hemoglobin ≥8 grams/deciliter (g/dL) (RBC TI) or maintaining platelets ≥20×109/L (platelet TI).
Time frame: Up to approximately 2.7 years
AML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI)
Transfusion independence was defined as no transfusion for 56 consecutive days or more (112 days) after the first dose of study treatment while maintaining hemoglobin ≥8 grams/deciliter (g/dL) (RBC TI) or maintaining platelets ≥20×109/L (platelet TI).
Time frame: Up to approximately 2.4 years
MDS/CMML: Leukemia-free Survival (LFS)
LFS was defined as time from the date of randomization to the date when bone marrow or peripheral blood blasts reach ≥20%, or death from any cause. Participants who hadn't reached AML at the time of the analysis were censored at the date of the last follow-up. Leukemia-free survival was presented using a Kaplan-Meier estimate.
Time frame: From randomization up to approximately 2.7 years
MDS/CMML: Overall Survival (OS)
OS was defined as time from the date of randomization to the date of death from any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. Overall survival was presented using a Kaplan-Meier estimate.
Time frame: From randomization up to approximately 2.7 years
AML: Overall Survival (OS)
OS was defined as time from the date of randomization to the date of death from any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. Overall survival was presented using a Kaplan-Meier estimate.
Time frame: From randomization up to approximately 2.4 years
AML: Survival Rates at 6 Months, 1 Year, and 2 Years
One-year survival rate was defined as the survival rate at the end of the first year from the date of randomization. The survival rates at 6 months and at 2 years were calculated similarly.
Time frame: At Month 6, Year 1 and 2
AML: Event-free Survival (EFS)
EFS was defined as time from the date of randomization to the date of treatment failure \[disease progression/relapse (due to confirmed reappearance of leukemic blasts in peripheral blood or ≥5% leukemic blasts in bone marrow (including relapse), discontinue treatment due to disease progression or treatment-related AE, or alternative anti-leukemia therapy except for HCT\] or death from any cause, whichever occurs first. Participants without documented treatment failure at the time of the analysis were censored at the date of the last follow-up. Event-free survival was presented using a Kaplan-Meier estimate.
Time frame: From randomization up to approximately 2.4 years
AML: Progression-free Survival (PFS)
PFS was defined as time from the date of randomization to the date disease progression due to confirmed reappearance of leukemic blasts in peripheral blood or ≥5% leukemic blasts in bone marrow (including relapse) or death from any cause, whichever occurs first. Participants without documented disease progression/relapse or death at the time of the analysis were censored at the date of the last follow-up. Progression-free survival was presented using a Kaplan-Meier estimate.
Time frame: From randomization up to approximately 2.4 years
A total of 227 participants took part in the study from 15 February 2018 to 25 May 2023. 138 participants with a diagnosis of myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) took part from the United States and Canada. 89 participants with a diagnosis of acute myeloid leukemia (AML) took part from Austria, Canada, Czech Republic, France, Germany, Hungary, Italy, Spain, and United Kingdom.
| Milestone | MDS or CMML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727 | MDS or CMML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727 | AML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727 | AML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727 |
|---|---|---|---|---|
| Started | 69 | 69 | 44 | 45 |
| Safety analysis set | 66 | 67 | 43 | 44 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 69 | 69 | 44 | 45 |
| Withdrew: Death | 33 | 25 | 34 | 34 |
| Withdrew: Complete consent withdrawal | 4 | 4 | 1 | 8 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 |
| Withdrew: Rollover to astx727-06 | 10 | 18 | 4 | 2 |
| Withdrew: Study centre terminated by sponsor | 21 | 22 | 4 | 1 |
Total 5-day ASTX727 AUC0-24 exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-24 (first ASTX727 dose) was added to (Day 2 AUC0-24+ Day 5 AUC0-24) × 2. Decitabine 5-day AUC0-24 exposures after IV decitabine were calculated as follows: (Day 1 AUC0-24+ Day 5 AUC0-24) / 2 was multiplied by 5. If AUC0-24 on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-24 on Day 5; the converse was also true.
| hours*nanograms per milliliter (h*ng/mL) | MDS or CMML: IV Decitabine | MDS or CMML: ASTX727 | AML: IV Decitabine | AML: ASTX727 |
|---|---|---|---|---|
| Total 5-day Area Under the Curve From 0 to 24 Hours (AUC0-24) After Treatment With ASTX727 And IV Decitabine | 864.34 ± 40.0 | 855.96 ± 50.6 | 910.1 ± 52.4 | 900.5 ± 52.0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first.
| Participants | MDS or CMML: IV Decitabine | MDS or CMML: ASTX727 |
|---|---|---|
| MDS/CMML: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 127 | 130 |
An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first.
| Participants | AML: IV Decitabine | AML: ASTX727 |
|---|---|---|
| AML: Number of Participants With Treatment-emergent Adverse Events (AEs) | 71 | 80 |
TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first. Severity of AEs were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal.
| Participants | MDS or CMML: IV Decitabine | MDS or CMML: ASTX727 |
|---|---|---|
| MDS/CMML: Number of Participants With Grade 3 or Higher TEAEs | 89 | 121 |
TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first. Severity of AEs were graded using CTCAE version 4.03. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal.
| Participants | AML: IV Decitabine | AML: ASTX727 |
|---|---|---|
| AML: Number of Participants With Grade 3 or Higher TEAEs | 43 | 73 |
Summarized data for Cycle 1 and Cycle 2 was reported.
| percentage of demethylation | MDS or CMML: IV Decitabine | MDS or CMML: ASTX727 | AML: IV Decitabine | AML: ASTX727 |
|---|---|---|---|---|
| Cycle 1 | 14.019 (12.528 to 15.510) | 13.289 (11.798 to 14.780) | 8.243 (6.340 to 10.147) | 9.357 (7.288 to 11.426) |
| Cycle 2 | 11.968 (10.503 to 13.434) | 11.151 (9.685 to 12.616) | 8.153 (6.226 to 10.079) | 8.037 (6.258 to 9.816) |
Total 5-day ASTX727 AUC0-inf exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-inf (first ASTX727 dose) was added to (Day 2 AUC0-inf+ Day 5 AUC0-inf) × 2. Decitabine 5-day AUC0-inf exposures after IV decitabine were calculated as follows: (Day 1 AUC0-inf+ Day 5 AUC0-inf) / 2 was multiplied by 5. If AUC0-inf on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-inf on Day 5; the converse was also true.
| h*ng/mL | MDS or CMML: IV Decitabine | MDS or CMML: ASTX727 | AML: IV Decitabine | AML: ASTX727 |
|---|---|---|---|---|
| Total 5-day Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine | 866.15 ± 39.9 | 849.63 ± 50.4 | 912.3 ± 52.3 | 902.1 ± 51.8 |
Total 5-day ASTX727 AUC0-last exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-last (first ASTX727 dose) was added to (Day 2 AUC0-last + Day 5 AUC0-last) × 2. Decitabine 5-day AUC0-last exposures after IV decitabine were calculated as follows: (Day 1 AUC0-last + Day 5 AUC0-last) / 2 was multiplied by 5. If AUC0-last on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-last on Day 5; the converse was also true.
| h*ng/mL | MDS or CMML: IV Decitabine | MDS or CMML: ASTX727 | AML: IV Decitabine | AML: ASTX727 |
|---|---|---|---|---|
| Total 5-day Area Under the Curve From 0 to Last Quantifiable Concentration (AUC0-last) After Treatment With ASTX727 And IV Decitabine | 853.02 ± 40.7 | 837.38 ± 50.7 | 902.7 ± 53.0 | 881.8 ± 52.5 |
Total 5-day ASTX727 AUC0-8 exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-8 (first ASTX727 dose) was added to (Day 2 AUC0-8 + Day 5 AUC0-8) × 2. Decitabine 5-day AUC0-8 exposures after IV decitabine were calculated as follows: (Day 1 AUC0-8 + Day 5 AUC0-8) / 2 was multiplied by 5. If AUC0-8 on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-8 on Day 5; the converse was also true.
| h*ng/mL | MDS or CMML: IV Decitabine | MDS or CMML: ASTX727 | AML: IV Decitabine | AML: ASTX727 |
|---|---|---|---|---|
| Total 5-day Area Under the Curve From 0 to 8 Hours (AUC0-8) After Treatment With ASTX727 And IV Decitabine | 856.63 ± 40.6 | 839.37 ± 50.4 | 910.1 ± 52.0 | 883.8 ± 52.1 |
AUC0-inf was calculated using the formula AUClast + (Clast / λZ), where Clast is the last quantifiable concentration and λZ is the elimination rate constant. AUC0-inf will be calculated using the linear up-log down method. Summarized data has been reported for cycle 1 and 2.
| nanograms*hours per millilitres(ng*h/mL) | MDS or CMML: IV Decitabine | MDS or CMML: ASTX727 | AML: IV Decitabine | AML: ASTX727 |
|---|---|---|---|---|
| Day 1 | 174 ± 40.8 | 102 ± 54.8 | 175 ± 54.9 | 118 ± 54.4 |
| Day 2 | — | 186 ± 55.3 | — | 193 ± 59.6 |
| Day 5 | 170 ± 41.7 | 178 ± 52.7 | 181 ± 58.1 | 187 ± 57.1 |
Summarized data of Cmax on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of Cmax on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.
| nanogram per milliliter (ng/mL) | MDS or CMML: IV Decitabine | MDS or CMML: ASTX727 | AML: IV Decitabine | AML: ASTX727 |
|---|---|---|---|---|
| Decitabine: Day 1 | 184 ± 48.1 | 83.1 ± 66.1 | 187 ± 64.7 | 85.9 ± 56.6 |
| Decitabine: Day 2 | — | 145 ± 54.7 | — | 139 ± 58.5 |
| Decitabine: Day 5 | 180 ± 49.2 | 140 ± 62.8 | 192 ± 62.4 | 139 ± 62.7 |
| Cedazuridine: Day 1 | — | 321 ± 53.8 | — | 313 ± 47.7 |
| Cedazuridine: Day 2 | — | 349 ± 49.1 | — | 343 ± 43.4 |
| Cedazuridine: Day 5 | — | 371 ± 51.8 | — | 350 ± 42.7 |
| Cedazuridine-epimer: Day 1 | — | 150 ± 65.7 | — | 182 ± 60.0 |
| Cedazuridine-epimer: Day 2 | — | 155 ± 64.6 | — | 204 ± 59.2 |
| Cedazuridine-epimer: Day 5 | — | 169 ± 65.9 | — | 191 ± 58.4 |
Summarized data of Tmax on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of Tmax on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.
| hours | MDS or CMML: IV Decitabine | MDS or CMML: ASTX727 | AML: IV Decitabine | AML: ASTX727 |
|---|---|---|---|---|
| Decitabine: Day 1 | 0.98 (0.23 to 1.27) | 1.00 (0.48 to 3.00) | 0.98 (0.25 to 2.00) | 1.00 (0.25 to 2.02) |
| Decitabine: Day 2 | — | 1.00 (0.47 to 2.00) | — | 1.00 (0.25 to 3.00) |
| Decitabine: Day 5 | 0.97 (0.25 to 1.62) | 1.00 (0.25 to 3.00) | 0.98 (0.00 to 1.17) | 1.00 (0.47 to 3.00) |
| Cedazuridine: Day 1 | — | 3.00 (1.50 to 7.97) | — | 3.98 (1.47 to 8.00) |
| Cedazuridine: Day 2 | — | 3.01 (0.52 to 7.88) | — | 4.00 (1.00 to 7.88) |
| Cedazuridine: Day 5 | — | 3.00 (1.50 to 6.12) | — | 3.98 (1.00 to 8.00) |
| Cedazuridine-epimer: Day 1 | — | 3.08 (1.50 to 7.97) | — | 4.00 (1.50 to 8.03) |
| Cedazuridine-epimer: Day 2 | — | 3.03 (0.52 to 7.88) | — | 4.00 (1.50 to 7.88) |
| Cedazuridine-epimer: Day 5 | — | 3.08 (1.00 to 8.05) | — | 4.00 (1.53 to 8.00) |
Oral CL/F for oral decitabine was measured only on Day 1 and oral CL/F for oral cedazuridine was measured on Days 1, 2 and 5. Summarized data of Oral CL/F for oral decitabine on Day 1 for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of oral CL/F for oral cedazuridine on Day 1,2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727.
| Litres per hour (L/h) | MDS or CMML: ASTX727 | AML: ASTX727 |
|---|---|---|
| Decitabine: Day 1 | 342 ± 54.8 | 297 ± 54.4 |
| Cedazuridine: Day 1 | 30.6 ± 46.4 | 28.6 ± 55.5 |
| Cedazuridine: Day 2 | 25.6 ± 159 | 27.4 ± 45.4 |
| Cedazuridine: Day 5 | 16.8 ± 15.9 | 86.8 ± NA |
Summarized data of t1/2 on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of t1/2 on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.
| hours | MDS or CMML: IV Decitabine | MDS or CMML: ASTX727 | AML: IV Decitabine | AML: ASTX727 |
|---|---|---|---|---|
| Decitabine: Day 1 | 0.967 ± 46.8 | 1.18 ± 22.8 | 1.16 ± 56.7 | 1.07 ± 31.6 |
| Decitabine: Day 2 | — | 1.38 ± 24.7 | — | 1.36 ± 35.0 |
| Decitabine: Day 5 | 1.14 ± 44.9 | 1.47 ± 26.9 | 1.18 ± 49.0 | 1.45 ± 34.0 |
| Cedazuridine: Day 1 | — | 6.33 ± 18.1 | — | 6.68 ± 18.5 |
| Cedazuridine: Day 2 | — | 6.70 ± 18.9 | — | 7.05 ± 17.6 |
| Cedazuridine: Day 5 | — | 2.59 ± 5.43 | — | 2.41 ± NA |
| Cedazuridine-epimer: Day 1 | — | 5.50 ± 21.8 | — | 6.22 ± 17.4 |
| Cedazuridine-epimer: Day 2 | — | 5.90 ± 23.2 | — | 6.15 ± 22.8 |
| Cedazuridine-epimer: Day 5 | — | 2.58 ± 5.16 | — | 2.57 ± NA |
Summarized data of Vz/F on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727.
| Litres | MDS or CMML: ASTX727 | AML: ASTX727 |
|---|---|---|
| Decitabine: Day 1 | 585 ± 55.0 | 434 ± 60.4 |
| Decitabine: Day 2 | 369 ± 59.0 | 337 ± 67.6 |
| Decitabine: Day 5 | 417 ± 54.3 | 373 ± 68.9 |
| Cedazuridine: Day 1 | 280 ± 50.9 | 272 ± 59.9 |
| Cedazuridine: Day 2 | 296 ± 51.3 | 278 ± 49.8 |
| Cedazuridine: Day 5 | 62.8 ± 10.4 | 302 ± NA |
CR: normal peripheral, persistent granulocyte count ≥1.0x10\^9/liter(L), platelet ≥100x10\^9/L, Hemoglobin (Hgb) ≥11g/dL, normal bone marrow with persistent marrow blasts ≤5%. mCR: reduction of bone marrow blasts to≤5%, decrease by 50% or more with/without normalization of peripheral counts.PR: normal peripheral counts, granulocyte count ≥1.0x10\^9/L, platelet count ≥100x10\^9/L, Hgb ≥11 g/dL, normal bone marrow, marrow blasts \>5%, reduced by 50% or more for at least 4 weeks. HI: HI-E: Hb increase ≥1.5 g/dL in absence of RBC transfusions. HI-P: Absolute increase of platelet count from \<20 to \>20X10\^9/L by at least 100%,if more than 20x10\^9/L, by absolute increase of at least 30x10\^9/L in absence of platelet transfusions. HI-N: granulocyte increase ≥100%, by an absolute increase ≥0.5x10\^9/L for at least 8 weeks. Percentage of participants with CR, mCR, PR, and HI based on IWG 2003 MDS response criteria are reported. Response has been reported based on participants with MDS or CMML.
| percentage of participants | MDS: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727 | MDS: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727 | CMML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727 | CMML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727 |
|---|---|---|---|---|
| Complete Response (CR) | 26.2 (15.8 to 39.1) | 19.6 (10.2 to 32.4) | 0 (0 to 0) | 18.2 (2.3 to 51.8) |
| Marrow Complete Response (mCR) | 29.5 (18.5 to 42.6) | 30.4 (18.8 to 44.1) | 40.0 (5.3 to 85.3) | 54.5 (23.4 to 83.3) |
| Partial Response (PR) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
| HI: Erythroid Response (HI-E) | 0 (0 to 0) | 1.8 (0.0 to 9.6) | 20.0 (0.5 to 71.6) | 0 (0 to 0) |
| HI: Platelet Response (HI-P) | 3.3 (0.4 to 11.3) | 8.9 (3.0 to 19.6) | 0 (0 to 0) | 0 (0 to 0) |
| HI: Neutrophil Response (HI-N) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 9.1 (0.2 to 41.3) |
CR was defined as absolute neutrophil content (ANC) ≥1000/ microliter (μL), platelets ≥100,000/μL, independence from red blood cell (RBC) and platelet transfusions over the past week, no leukemic blasts and \<5% leukemic blasts. CRp was defined as CR criteria except platelets \<100,000/μL.and platelet transfusion over the past week. CRi was defined as CR criteria except ANC \<1000/μL or platelets \<100,000/μL. Percentage of participants with CR, CRi, CRp, and CR Plus CRp based on IWG 2003 AML response criteria are reported.
| percentage of participants | AML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727 | AML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727 |
|---|---|---|
| Complete Response (CR) | 14.0 (5.3 to 27.9) | 29.5 (16.8 to 45.2) |
| CR with Incomplete Platelet Recovery (CRp) | 4.7 (0.6 to 15.8) | 0 (0.0 to 8.0) |
| CR with Incomplete Blood Count Recovery (CRi) | 11.6 (3.9 to 25.1) | 0 (0.0 to 8.0) |
| CR Plus CRp | 18.6 (8.4 to 33.4) | 29.5 (16.8 to 45.2) |
CRh was defined as \<5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets \>50,000/μL and ANC \>500/μL), independence from RBC and platelet transfusions within 7 days of bone marrow evaluation, and peripheral blast ≤1%. Percentage of participants with CRh based on IWG 2003 AML response criteria are reported.
| percentage of participants | AML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727 | AML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727 |
|---|---|---|
| AML: Percentage of Participants With CR With Partial Hematologic Recovery (CRh) Based on IWG 2003 AML Response Criteria | 4.7 (0.6 to 15.8) | 0 (0.0 to 8.0) |
Time to first response was defined as time in months from the date of first treatment to the first date when any response is achieved. Time to best response was defined in months from the date of first treatment to the first date when a subject's best response, in the order of CR, CRi (or CRp or CRh), or PR, was achieved. Time to CR was defined in months from the date of first treatment to the first date when CR is achieved. CR:ANC ≥1000/ microliter (μL),platelets ≥100,000/μL,independence from RBC and platelet transfusions over the past week, no leukemic blasts, and \<5% leukemic blasts.CRp: CR criteria except ANC ≥1000/μL, platelets \< 100,000/μL.and platelet transfusion over the past week. CRi:CR criteria except ANC \<1000/μL or platelets \<100,000/μL.CRh: \<5% of blasts in the bone marrow,platelets \>50,000/μL and ANC \>500/μL, independence from RBC and platelet transfusions within 7 days and peripheral blast ≤1%. PR: CR criteria except decrease of ≥50% in leukemic blasts.
| months | AML: ASTX727 or IV Decitabine |
|---|---|
| Time to First Response | 2.91 (1.9 to 6.5) |
| Time to Best Response | 3.45 (1.9 to 7.5) |
| Time to Complete Response | 3.02 (1.9 to 7.5) |
Duration of CR was defined as the time interval from the first CR to time of relapse. Duration of combined CR and CRh was defined as the time interval from the first CR or CRh to time of relapse. Duration of CR and combined CR and CRh was presented using a Kaplan-Meier estimate.
| months | AML: ASTX727 or IV Decitabine |
|---|---|
| Duration of Complete Response | 6.9 (3.4 to 11.5) |
| Duration of Combined CR and CRh | 9.0 (3.4 to 11.5) |
Transfusion independence was defined as no transfusion for 56 consecutive days or more (84 and 112 days) after the first dose of study treatment while maintaining hemoglobin ≥8 grams/deciliter (g/dL) (RBC TI) or maintaining platelets ≥20×109/L (platelet TI).
| percentage of participants | MDS or CMML: ASTX727 or IV Decitabine |
|---|---|
| RBC TI: ≥56 Days | 51.9 (37.8 to 65.7) |
| RBC TI: ≥84 Days | 40.7 (27.6 to 55.0) |
| RBC TI: ≥112 Days | 33.3 (21.1 to 47.5) |
| Platelet TI: ≥56 Days | 50.0 (21.1 to 78.9) |
| Platelet TI: ≥84 Days | 33.3 (9.9 to 65.1) |
| Platelet TI: ≥112 Days | 33.3 (9.9 to 65.1) |
Transfusion independence was defined as no transfusion for 56 consecutive days or more (112 days) after the first dose of study treatment while maintaining hemoglobin ≥8 grams/deciliter (g/dL) (RBC TI) or maintaining platelets ≥20×109/L (platelet TI).
| percentage of participants | AML: ASTX727 or IV Decitabine |
|---|---|
| RBC TI ≥56 Days | 37.8 (22.5 to 55.2) |
| RBC TI ≥112 Days | 24.3 (11.8 to 41.2) |
| Platelet TI ≥56 Days | 35.7 (12.8 to 64.9) |
| Platelet TI ≥112 Days | 28.6 (8.4 to 58.1) |
LFS was defined as time from the date of randomization to the date when bone marrow or peripheral blood blasts reach ≥20%, or death from any cause. Participants who hadn't reached AML at the time of the analysis were censored at the date of the last follow-up. Leukemia-free survival was presented using a Kaplan-Meier estimate.
| days | MDS or CMML: ASTX727 or IV Decitabine |
|---|---|
| MDS/CMML: Leukemia-free Survival (LFS) | 889.0 (674.0 to NA) |
OS was defined as time from the date of randomization to the date of death from any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. Overall survival was presented using a Kaplan-Meier estimate.
| days | MDS or CMML: ASTX727 or IV Decitabine |
|---|---|
| MDS/CMML: Overall Survival (OS) | 966.0 (809.0 to NA) |
OS was defined as time from the date of randomization to the date of death from any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. Overall survival was presented using a Kaplan-Meier estimate.
| months | AML: ASTX727 or IV Decitabine |
|---|---|
| AML: Overall Survival (OS) | 8.9 (5.9 to 13.1) |
One-year survival rate was defined as the survival rate at the end of the first year from the date of randomization. The survival rates at 6 months and at 2 years were calculated similarly.
| percentage of participants | AML: ASTX727 or IV Decitabine |
|---|---|
| Month 6 | 61 (50 to 71) |
| Year 1 | 44 (33 to 54) |
| Year 2 | 16 (8 to 26) |
EFS was defined as time from the date of randomization to the date of treatment failure \[disease progression/relapse (due to confirmed reappearance of leukemic blasts in peripheral blood or ≥5% leukemic blasts in bone marrow (including relapse), discontinue treatment due to disease progression or treatment-related AE, or alternative anti-leukemia therapy except for HCT\] or death from any cause, whichever occurs first. Participants without documented treatment failure at the time of the analysis were censored at the date of the last follow-up. Event-free survival was presented using a Kaplan-Meier estimate.
| months | AML: ASTX727 or IV Decitabine |
|---|---|
| AML: Event-free Survival (EFS) | 5.9 (3.8 to 8.5) |
PFS was defined as time from the date of randomization to the date disease progression due to confirmed reappearance of leukemic blasts in peripheral blood or ≥5% leukemic blasts in bone marrow (including relapse) or death from any cause, whichever occurs first. Participants without documented disease progression/relapse or death at the time of the analysis were censored at the date of the last follow-up. Progression-free survival was presented using a Kaplan-Meier estimate.
| months | AML: ASTX727 or IV Decitabine |
|---|---|
| AML: Progression-free Survival (PFS) | 6.1 (4.0 to 8.7) |
Collected over MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MDS or CMML: IV Decitabine | 2/132 (1.5%) | 24/132 (18.2%) | 127/132 (96.2%) |
| MDS or CMML: ASTX727 | 56/130 (43.1%) | 81/130 (62.3%) | 130/130 (100%) |
| MDS or CMML: Not Treated | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| AML: IV Decitabine | 5/78 (6.4%) | 19/78 (24.4%) | 70/78 (89.7%) |
| AML: ASTX727 | 61/80 (76.3%) | 65/80 (81.3%) | 76/80 (95%) |
| AML: Not Treated | 2/2 (100%) | 1/2 (50%) | 0/2 (0%) |
| Event | MDS or CMML: IV Decitabine | MDS or CMML: ASTX727 | MDS or CMML: Not Treated | AML: IV Decitabine | AML: ASTX727 | AML: Not Treated |
|---|---|---|---|---|---|---|
| Sudden DeathGeneral disorders | 0/132 | 0/130 | 0/5 | 0/78 | 1/80 | 1/2 |
| Febrile neutropeniaBlood and lymphatic system disorders | 8/132 | 33/130 | 0/5 | 4/78 | 21/80 | 0/2 |
| PneumoniaInfections and infestations | 6/132 | 17/130 | 0/5 | 4/78 | 16/80 | 0/2 |
| SepsisInfections and infestations | 0/132 | 10/130 | 0/5 | 0/78 | 3/80 | 0/2 |
| InfectionInfections and infestations | 0/132 | 0/130 | 0/5 | 1/78 | 5/80 | 0/2 |
| AnaemiaBlood and lymphatic system disorders | 0/132 | 2/130 | 0/5 | 0/78 | 4/80 | 0/2 |
| CellulitisInfections and infestations | 2/132 | 5/130 | 0/5 | 1/78 | 4/80 | 0/2 |
| AstheniaGeneral disorders | 1/132 | 2/130 | 0/5 | 0/78 | 3/80 | 0/2 |
| Urinary tract infectionInfections and infestations | 0/132 | 1/130 | 0/5 | 0/78 | 3/80 | 0/2 |
| BronchitisInfections and infestations | 0/132 | 0/130 | 0/5 | 0/78 | 3/80 | 0/2 |
| Event | MDS or CMML: IV Decitabine | MDS or CMML: ASTX727 | MDS or CMML: Not Treated | AML: IV Decitabine | AML: ASTX727 | AML: Not Treated |
|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 52/132 | 90/130 | 0/5 | 30/78 | 47/80 | 0/2 |
| NeutropeniaBlood and lymphatic system disorders | 45/132 | 79/130 | 0/5 | 8/78 | 27/80 | 0/2 |
| AnaemiaBlood and lymphatic system disorders | 47/132 | 72/130 | 0/5 | 21/78 | 41/80 | 0/2 |
| FatigueGeneral disorders | 23/132 | 68/130 | 0/5 | 2/78 | 9/80 | 0/2 |
| ConstipationGastrointestinal disorders | 26/132 | 64/130 | 0/5 | 8/78 | 15/80 | 0/2 |
| NauseaGastrointestinal disorders | 23/132 | 63/130 | 0/5 | 4/78 | 17/80 | 0/2 |
| DiarrhoeaGastrointestinal disorders | 14/132 | 54/130 | 0/5 | 1/78 | 17/80 | 0/2 |
| HeadacheNervous system disorders | 19/132 | 50/130 | 0/5 | 2/78 | 6/80 | 0/2 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 12/132 | 45/130 | 0/5 | 3/78 | 4/80 | 0/2 |
| Decreased AppetiteMetabolism and nutrition disorders | 7/132 | 43/130 | 0/5 | 5/78 | 12/80 | 0/2 |
The Safety Analysis Set included all participants who received any amount of study treatment.
| Age, Customized(Participants) | MDS or CMML: ASTX727 or IV Decitabine | AML: ASTX727 or IV Decitabine | Total |
|---|---|---|---|
| 18 to 64 years | 36 | 3 | 39 |
| 65 to 84 years | 93 | 75 | 168 |
| ≥85 years | 4 | 9 | 13 |
| Sex: Female, Male(Participants) | MDS or CMML: ASTX727 or IV Decitabine | AML: ASTX727 or IV Decitabine | Total |
|---|---|---|---|
| Female | 46 | 34 | 80 |
| Male | 87 | 53 | 140 |
| Ethnicity (NIH/OMB)(Participants) | MDS or CMML: ASTX727 or IV Decitabine | AML: ASTX727 or IV Decitabine | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 0 | 6 |
| Not Hispanic or Latino | 125 | 0 | 125 |
| Unknown or Not Reported | 2 | 87 | 89 |
| Race (NIH/OMB)(Participants) | MDS or CMML: ASTX727 or IV Decitabine | AML: ASTX727 or IV Decitabine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 0 | 4 |
| White | 121 | 0 | 121 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 87 | 92 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Sep 2021, 42 months.
Results were first posted in Jul 2024, 2 years 9 months after primary completion. A results delay was requested in Jul 2022.
Of 26 industry-sponsored phase 3 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 52. This study's 42 months is close to that.
Counting every sponsor, half of 46 studies reached it within 48 months; a quarter within 37 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.